公开(公告)号：US12178981B2

公开(公告)日：2024-12-31

申请号：US16958388

申请日：2018-12-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Naoyuki Murata ,  Shigeo Yanai

IPC: A61M37/00 ,  A61K41/00 ,  A61K49/22

Abstract: The present disclosure provides a safer novel opening system with highly broad utility for a blood-brain barrier (BBB), the opening system containing a combination of (1) nano-bubble water or nano-bubble aqueous solution containing nano-bubbles having an average diameter of not more than 200 nm, and (2) an ultrasound generating apparatus; a method for opening a BBB, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound; and a method for increasing BBB permeability of a drug, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound.

公开(公告)号：US20240394881A1

公开(公告)日：2024-11-28

申请号：US18795513

申请日：2024-08-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Uday Veer Manish Bangia ,  Elliot Greenblatt ,  Daniel Alexander Leffler ,  Jenifer R.Q.W. Siegelman ,  Ozlem Nurcan Yardibi

IPC: G06T7/00 ,  G06F16/383 ,  G06F18/21 ,  G06T7/12 ,  G06T7/13 ,  G06V10/764 ,  G06V10/82

Abstract: Disclosed herein are computer-implemented method, system, and computer-program product (computer-readable storage medium) embodiments of image scoring for intestinal pathology. An embodiment includes receiving, via at least one processor, an output of an imaging device. The output of the imaging device may include a plurality of image frames forming at least a subset of a set of image frames depicting an inside surface of a digestive organ of a given patient; and decomposing, via at least one machine learning (ML) algorithm, at least one image frame of the plurality of image frames into a plurality of regions of interest. The at least one region of interest may be defined by determining that an edge value exceeds a predetermined threshold. At least one processor may automatically assign a first score based at least in part on the edge value for each region of interest and automatically shuffle the set of image frames.

公开(公告)号：US20240382482A1

公开(公告)日：2024-11-21

申请号：US18550571

申请日：2022-03-16

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Nikolaos PAPAIOANNOU ,  Jeremy Mark TRAVINS ,  Sarah Jocelyn FINK ,  John Mark ELLARD ,  Alastair RAE ,  Jonathan Andrew SPENCER

IPC: A61K31/506 ,  C07D519/00

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

公开(公告)号：US20240374721A1

公开(公告)日：2024-11-14

申请号：US18292574

申请日：2022-07-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Chihiro Take ,  Gary Shapiro ,  Yoshiaki Kassai ,  Xingyue He ,  Chantal Kuhn

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/52 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783

Abstract: Disclosed herein are engineered immune cells that specifically recognizes mesothelin and expresses IL-15 and optionally CCL19. Also disclosed herein are isolated nucleic acid molecules comprising a polynucleotide encoding a chimeric antigen receptor (CAR) comprising an antibody that specifically recognizes mesothelin, and a 4-IBB intracellular region; and a polynucleotide encoding IL-15; and optionally a polynucleotide encoding CCL19, vectors, pharmaceutical compositions comprising the nucleic acid molecules, and methods of using the engineered immune cells.

公开(公告)号：US12135329B2

公开(公告)日：2024-11-05

申请号：US18308813

申请日：2023-04-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jiang Wu ,  Guodong Zhang ,  Daniel J. Sexton ,  Ryan Faucette ,  Gul M. Mustafa ,  Mark Szewc

IPC: G01N33/68 ,  G01N30/72 ,  G01N30/88 ,  G01N30/02

Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.

公开(公告)号：US20240350544A1

公开(公告)日：2024-10-24

申请号：US18640982

申请日：2024-04-19

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Michael Curley ,  Ertan Eryilmaz ,  Shawn Jennings ,  LeeAnn Talarico ,  Taylor Hickman ,  Christina Sheau Fen Wong ,  Kathryn Fraser ,  Haiqing Wang ,  Alessandra Piersigilli

IPC: A61K35/17 ,  A61K39/00 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464416 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/2878 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/25 ,  A61K2239/48 ,  C07K2317/565

Abstract: This present invention relates to BCMA binders (e.g. antibodies) and chimeric antigen receptor (CAR) constructs comprising a BCMA antigen binding molecule. The BCMA binders specifically bind to BCMA. The present BCMA CARs further comprise a hinge region (e.g., CD28 hinge), a transmembrane domain, and one or more intracellular NK cell signalling domains. NK cells expressing a BCMA CAR has increased efficacy in killing cancer cells. Provided herein also include therapeutic uses of the BCMA binders and BCMA CARs.

公开(公告)号：US12121569B2

公开(公告)日：2024-10-22

申请号：US17578119

申请日：2022-01-18

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Gaozhong Zhu ,  Kris Lowe ,  Zahra Shahrokh ,  James Christian ,  Richard Fahrner ,  Jing Pan ,  Teresa Leah Wright ,  Pericles Calias

IPC: A61K38/47 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K35/76 ,  A61K35/761 ,  A61K38/46 ,  A61K47/02 ,  A61K47/26 ,  C07K14/65 ,  C12N9/24 ,  C12N9/42

CPC classification number: A61K38/47 ,  A61K9/0019 ,  A61K9/0085 ,  A61K9/08 ,  A61K9/19 ,  A61K35/76 ,  A61K35/761 ,  A61K38/46 ,  A61K38/465 ,  A61K47/02 ,  A61K47/26 ,  C07K14/65 ,  C12N9/2402 ,  C12N9/2437 ,  C12Y301/06008 ,  C12Y301/06013 ,  C12Y302/01045 ,  C12Y302/01046 ,  C12Y302/0105 ,  C12Y310/01001

Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

公开(公告)号：US12110343B2

公开(公告)日：2024-10-08

申请号：US17684460

申请日：2022-03-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Andrew Nixon ,  Jon A. Kenniston ,  Stephen R. Comeau

IPC: C07K16/40

CPC classification number: C07K16/40 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.

公开(公告)号：US12097199B2

公开(公告)日：2024-09-24

申请号：US17258845

申请日：2019-07-08

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Sai Murali Krishna Pulukuri

IPC: A61K31/505 ,  A61P35/02 ,  C07K16/28

CPC classification number: A61K31/505 ,  A61P35/02 ,  C07K16/2887

Abstract: The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer or autoimmune disease in patients in need thereof. The methods comprise administering to a patient in need a small ubiquitin-like modifier (SUMO) activating enzyme (SAE) inhibitor, such as [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxy-cyclopentyl]methyl sulfamate (Compound I-263a) or a pharmaceutically acceptable salt, in combination with one or more anti-CD20 antibodies. Also provided are medicaments for use in treating cancer or autoimmune disease.

公开(公告)号：US12097198B2

公开(公告)日：2024-09-24

申请号：US17866203

申请日：2022-07-15

Applicant: Sumitomo Pharma Switzerland GmbH ,  Takeda Pharmaceutical Company Limited

Inventor： Vijaykumar Reddy Rajasekhar ,  Brendan Mark Johnson ,  David B. Maclean ,  Lynn Seely ,  Paul N. Mudd, Jr. ,  Hélène M. Faessel

IPC: A61K31/517 ,  A61K9/00 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/501 ,  A61K31/513 ,  A61P35/00

CPC classification number: A61K31/501 ,  A61K9/0053 ,  A61K31/4166 ,  A61K31/513 ,  A61P35/00

Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.